Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

Inclusion Criteria:

• Participants, who completed the last treatment visit of the previous double-blindbrexpiprazole BPD trial and who, in the opinion of the investigator, couldpotentially benefit from administration of brexpiprazole for the treatment of BPD.

• Male or female outpatients, ages 18 to 65 years, inclusive, at the time of informedconsent of the previous double-blind brexpiprazole BPD trial.

Exclusion Criteria:

• Sexually active males or females of childbearing potential (FOCBP) who do not agreeto practice 2 different methods of birth control or remain abstinent during thetrial and for 30 days after the last dose of IMP. Male participants must also agreenot to donate sperm from trial screening/baseline through 30 days after the lastdose of investigational medicinal product (IMP).

• Women who are breastfeeding and/or who have a positive pregnancy test result priorto receiving IMP.

• Participants who participated in a clinical trial within 90 days prior toscreening/baseline (with the exception of a previous brexpiprazole double-blind BPDtrial) or who participated in more than 2 clinical trials within a year prior toscreening/baseline.

• Participants who develop a medically significant abnormality.